Aquestive Therapeutics, Inc. (NASDAQ:AQST) Sees Large Drop in Short Interest

Aquestive Therapeutics, Inc. (NASDAQ:AQST) was the recipient of a large decrease in short interest in the month of January. As of January 31st, there was short interest totalling 11,090,000 shares, a decrease of 5.9% from the January 15th total of 11,790,000 shares. Based on an average daily volume of 1,470,000 shares, the short-interest ratio is currently 7.5 days.

Institutional Investors Weigh In On Aquestive Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the stock. Price T Rowe Associates Inc. MD grew its holdings in Aquestive Therapeutics by 16.0% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 27,669 shares of the company’s stock valued at $99,000 after buying an additional 3,821 shares in the last quarter. MetLife Investment Management LLC grew its holdings in shares of Aquestive Therapeutics by 11.4% in the fourth quarter. MetLife Investment Management LLC now owns 40,221 shares of the company’s stock valued at $143,000 after purchasing an additional 4,125 shares in the last quarter. Bank of Montreal Can grew its holdings in shares of Aquestive Therapeutics by 10.1% in the fourth quarter. Bank of Montreal Can now owns 54,300 shares of the company’s stock valued at $193,000 after purchasing an additional 4,999 shares in the last quarter. Financial Advocates Investment Management lifted its position in Aquestive Therapeutics by 14.7% in the third quarter. Financial Advocates Investment Management now owns 39,000 shares of the company’s stock worth $194,000 after buying an additional 5,000 shares during the last quarter. Finally, nVerses Capital LLC bought a new stake in Aquestive Therapeutics in the third quarter worth $28,000. 32.45% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts have recently weighed in on AQST shares. HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of Aquestive Therapeutics in a research note on Friday, December 20th. Cantor Fitzgerald started coverage on shares of Aquestive Therapeutics in a research note on Tuesday, December 17th. They issued an “overweight” rating and a $17.00 price objective on the stock. Finally, Leerink Partners increased their price objective on shares of Aquestive Therapeutics from $12.00 to $13.00 and gave the stock an “outperform” rating in a research note on Friday, October 25th. Six equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $11.00.

Aquestive Therapeutics Trading Down 5.1 %

NASDAQ AQST opened at $3.15 on Wednesday. Aquestive Therapeutics has a 12 month low of $2.24 and a 12 month high of $6.23. The stock has a market cap of $287.22 million, a price-to-earnings ratio of -7.00 and a beta of 2.67. The company’s 50 day moving average is $3.32 and its two-hundred day moving average is $4.19.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.